Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients
- 11 June 2014
- journal article
- research article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 45 (3) , 1293-1303
Abstract
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publicationsKeywords
This publication has 37 references indexed in Scilit:
- Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma PatientsClinical Cancer Research, 2011
- Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancerExpert Review of Vaccines, 2010
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJAMA, 2007
- Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancerCancer Immunology, Immunotherapy, 2006
- Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer PatientsJournal of Clinical Oncology, 2005
- Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreasCancer Immunology, Immunotherapy, 2005
- Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinationsPancreatology, 2005
- New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric CancersThe Oncologist, 2004
- Pancreatic cancerThe Lancet, 2004
- Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T CellsThe Journal of Immunology, 2003